tetano
Editor, Senior Moderator
Vaccine. 2013 Dec 11. pii: S0264-410X(13)01662-9. doi: 10.1016/j.vaccine.2013.11.073. [Epub ahead of print]
Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients.
Dh?din N1, Krivine A2, Le Corre N3, Mallet A4, Lioure B5, Bay JO6, Rubio MT7, Agape P8, Thi?baut A9, Le Goff J10, Autran B3, Ribaud P11.
Author information
Abstract
BACKGROUND:
The present study evaluated immunogenicity and tolerance of two-dose influenza A/H1N1pdm09 vaccination in allogeneic hematopoietic stem cell transplantation (HSCT) recipients, and compared the vaccine-induced humoral response to that triggered by natural infection in another group of HSCT patients.
METHODS:
Adult allogeneic HSCT recipients vaccinated with two doses of influenza A/H1N1pdm09 vaccine, separated by 3 weeks, and patients with proven influenza A/H1N1pdm09 infection were included. Antibody responses were measured by hemagglutination-inhibition assay (1) on days 0, 21, 42 and 6 months after the first vaccine injection in vaccinated patients and (2) before pandemic and after influenza A/H1N1pdm09 infection, in patients presented natural infection.
RESULTS:
At baseline, 3% of 59 recipients of adjuvanted vaccine and 0% of 20 infected patients were seroprotected (antibody titer≥1/40). Seroprotection rate observed 42 days after vaccination was not different from that observed after natural infection (66% and 60% respectively, p=0.78). In vaccinated patients, seroprotection rate increased significantly from 54% to 66% between day 21 and 42 (p=0.015). Moreover, after 6 months, seroprotection rate in 21 vaccinated patients was similar to that observed in 10 infected patients evaluated at least 76 days after infection (D76-217) (60% and 81% respectively, p=0.2). In multivariate analysis, no immunosuppressive treatment or chronic graft-versus-host disease (GVHD) and longer time between transplantation and vaccination/infection were associated with a stronger humoral response. The adjuvanted vaccine was safe with low rate of GVHD worsening.
CONCLUSION:
In HSCT recipients, two doses of influenza A/H1N1pdm09 adjuvanted vaccine were safe and induced a humoral response comparable to that triggered by natural infection in these patients.
Copyright ? 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.
KEYWORDS:
Hematopoietic stem cell transplantation, Humoral immune response, Influenza A/H1N1pdm09 infection, Influenza vaccination
PMID:
24333120
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24333120
Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients.
Dh?din N1, Krivine A2, Le Corre N3, Mallet A4, Lioure B5, Bay JO6, Rubio MT7, Agape P8, Thi?baut A9, Le Goff J10, Autran B3, Ribaud P11.
Author information
Abstract
BACKGROUND:
The present study evaluated immunogenicity and tolerance of two-dose influenza A/H1N1pdm09 vaccination in allogeneic hematopoietic stem cell transplantation (HSCT) recipients, and compared the vaccine-induced humoral response to that triggered by natural infection in another group of HSCT patients.
METHODS:
Adult allogeneic HSCT recipients vaccinated with two doses of influenza A/H1N1pdm09 vaccine, separated by 3 weeks, and patients with proven influenza A/H1N1pdm09 infection were included. Antibody responses were measured by hemagglutination-inhibition assay (1) on days 0, 21, 42 and 6 months after the first vaccine injection in vaccinated patients and (2) before pandemic and after influenza A/H1N1pdm09 infection, in patients presented natural infection.
RESULTS:
At baseline, 3% of 59 recipients of adjuvanted vaccine and 0% of 20 infected patients were seroprotected (antibody titer≥1/40). Seroprotection rate observed 42 days after vaccination was not different from that observed after natural infection (66% and 60% respectively, p=0.78). In vaccinated patients, seroprotection rate increased significantly from 54% to 66% between day 21 and 42 (p=0.015). Moreover, after 6 months, seroprotection rate in 21 vaccinated patients was similar to that observed in 10 infected patients evaluated at least 76 days after infection (D76-217) (60% and 81% respectively, p=0.2). In multivariate analysis, no immunosuppressive treatment or chronic graft-versus-host disease (GVHD) and longer time between transplantation and vaccination/infection were associated with a stronger humoral response. The adjuvanted vaccine was safe with low rate of GVHD worsening.
CONCLUSION:
In HSCT recipients, two doses of influenza A/H1N1pdm09 adjuvanted vaccine were safe and induced a humoral response comparable to that triggered by natural infection in these patients.
Copyright ? 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.
KEYWORDS:
Hematopoietic stem cell transplantation, Humoral immune response, Influenza A/H1N1pdm09 infection, Influenza vaccination
PMID:
24333120
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24333120